Silence Therapeutics plc (SLN)
|52 Week Range||4.545-17.99|
|1y Target Est||-|
|DCF Unlevered||SLN DCF ->|
|DCF Levered||SLN LDCF ->|
|Debt / Equity||2.97%||Neutral|
Upgrades & Downgrades
Latest SLN news
Silence Therapeutics: No Reason For It To Fall So Much
14 July 2023
SLN has fallen 65% after my last article. They produced good early data, they have decent cash, and there's no negative news. I can identify no reason for the stock to have declined so much.
New Strong Sell Stocks for May 9th
9 May 2023
ARCB, MRVL and SLN have been added to the Zacks Rank #5 (Strong Sell) List on May 9, 2023.
Silence Therapeutics plc (SLN) Q4 2022 Earnings Call Transcript
15 March 2023
Silence Therapeutics plc (NASDAQ:SLN ) Q4 2022 Earnings Conference Call March 15, 2023 8:00 AM ET Company Participants Gem Hopkins - Head of Investor Relations & Corporate Communications Craig Tooman ...
Silence Therapeutics: Breaking The Silence On An Under-The-Radar Mid-Stage SiRNA Platform
13 March 2023
Silence Therapeutics is an underfollowed British siRNA company focusing on cardiovascular and autoimmune diseases. Silence Therapeutics is a de-risked investment opportunity with significant potential...
Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?
6 March 2023
Silence Therapeutics PLC Sponsored ADR (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue movin...
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
18 January 2023
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock...
4 January 2023
Silence Therapeutics PLC Sponsored ADR (SLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in...
Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
3 January 2023
LONDON--( BUSINESS WIRE )--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing...
Silence Therapeutics: Excellent Data In A Cardiovascular Indication
6 December 2022
SLN is a gene silencing therapy developer. SLN produced excellent data from its lead candidate.